What does R2 FARMA do?

R2 FARMA is filed with the CBE under the catch-all “Overige zakelijke dienstverlening”, a code that says little about what the company actually does. Private Limited, started on 24 December 2011, 1 establishment.

What is the address of R2 FARMA?

The registered office of R2 FARMA is located at Vilvoordelaan 74, 1930 Zaventem.

Is R2 FARMA still active?

Yes. According to the CBE (16 September 2026) R2 FARMA is active, legal situation “Normale toestand”, started on 24 December 2011.

Is R2 FARMA registered on Peppol?

Yes, R2 FARMA is registered on the Peppol network with ID 0208:0842118663.

What is the enterprise number of R2 FARMA?

The enterprise number of R2 FARMA is BE0842118663.

When was R2 FARMA founded?

R2 FARMA was founded on 24 December 2011.

Who are the directors of R2 FARMA?

According to the 2025 annual accounts, the directors of R2 FARMA are: Leen Roggen, Tim Roosens.

Is R2 FARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 24 December 2011; 4 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did R2 FARMA make in 2025?

R2 FARMA posted a profit after taxes of € 288,361 in financial year 2025.

What is the revenue of R2 FARMA?

As a small company, R2 FARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 467,487.

R2 FARMA (Private Limited) - Zaventem - BE0842118663

Dossier R2 FARMA, printed on 16 September 2026 from databakkes.be/en/0842118663/r2-farma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 17 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

R2 FARMA from Zaventem, company number BE0842118663, closed financial year 2025 with a result of € 288,361 after tax. For that financial year R2 FARMA recorded a gross margin of € 467,487 and equity of € 2.3 million. Compared with financial year 2024, the result moved from € 350,921 to € 288,361. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on November 27, 2025.

What it is worth Growing

€ 2.3 million

▲ 15% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 288,361

▼ 18% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 17,064

▼ 3% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 2.1 million.

People and assets in 2025

Vehicles and equipment

€ 41,684

▼ 25% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 7 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 2.2 million

▼ 13% vs 2024

€ 325,306 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.

Owed to suppliers

€ 371

▼ 91% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 42,201

▲ 6% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 439,610 Gross margin 2022: € 439,610 First fiscal year in the series	€ 450,368 Gross margin 2023: € 450,368 ▲ 2% vs 2022 (€ 439,610) Favourable step	€ 539,734 Gross margin 2024: € 539,734 ▲ 20% vs 2023 (€ 450,368) Favourable step	€ 467,487 Gross margin 2025: € 467,487 ▼ 13% vs 2024 (€ 539,734) Unfavourable step	▼ 13%
Profit after taxes	€ 273,966 Profit after taxes 2022: € 273,966 First fiscal year in the series	€ 285,862 Profit after taxes 2023: € 285,862 ▲ 4% vs 2022 (€ 273,966) Favourable step	€ 350,921 Profit after taxes 2024: € 350,921 ▲ 23% vs 2023 (€ 285,862) Favourable step	€ 288,361 Profit after taxes 2025: € 288,361 ▼ 18% vs 2024 (€ 350,921) Unfavourable step	▼ 18%
Equity	€ 1,349,853 Equity 2022: € 1,349,853 First fiscal year in the series	€ 1,635,715 Equity 2023: € 1,635,715 ▲ 21% vs 2022 (€ 1,349,853) Favourable step	€ 1,986,636 Equity 2024: € 1,986,636 ▲ 21% vs 2023 (€ 1,635,715) Favourable step	€ 2,274,996 Equity 2025: € 2,274,996 ▲ 15% vs 2024 (€ 1,986,636) Favourable step	▲ 15%
Total debts	€ 3,419,851 Total debts 2022: € 3,419,851 First fiscal year in the series	€ 3,168,661 Total debts 2023: € 3,168,661 ▼ 7% vs 2022 (€ 3,419,851) Favourable step	€ 2,832,286 Total debts 2024: € 2,832,286 ▼ 11% vs 2023 (€ 3,168,661) Favourable step	€ 2,513,397 Total debts 2025: € 2,513,397 ▼ 11% vs 2024 (€ 2,832,286) Favourable step	▼ 11%
Cash	€ 17,890 Cash 2022: € 17,890 First fiscal year in the series	€ 1,609 Cash 2023: € 1,609 ▼ 91% vs 2022 (€ 17,890) Unfavourable step	€ 17,551 Cash 2024: € 17,551 ▲ € 15,942 vs 2023 (€ 1,609) Favourable step	€ 17,064 Cash 2025: € 17,064 ▼ 3% vs 2024 (€ 17,551) Unfavourable step	▼ 3%
Land & buildings	€ 220,940 Land & buildings 2022: € 220,940 First fiscal year in the series	€ 220,402 Land & buildings 2023: € 220,402 Unchanged (€ 220,940) Unchanged	€ 210,477 Land & buildings 2024: € 210,477 ▼ 5% vs 2023 (€ 220,402) Unchanged	€ 197,103 Land & buildings 2025: € 197,103 ▼ 6% vs 2024 (€ 210,477) Unchanged	▼ 6%
Retained profit	€ 1,199,853 Retained profit 2022: € 1,199,853 First fiscal year in the series	€ 1,485,715 Retained profit 2023: € 1,485,715 ▲ 24% vs 2022 (€ 1,199,853) Favourable step	€ 1,836,636 Retained profit 2024: € 1,836,636 ▲ 24% vs 2023 (€ 1,485,715) Favourable step	€ 2,124,996 Retained profit 2025: € 2,124,996 ▲ 16% vs 2024 (€ 1,836,636) Favourable step	▲ 16%
Bank debt	€ 3,120,245 Bank debt 2022: € 3,120,245 First fiscal year in the series	€ 2,889,292 Bank debt 2023: € 2,889,292 ▼ 7% vs 2022 (€ 3,120,245) Favourable step	€ 2,580,448 Bank debt 2024: € 2,580,448 ▼ 11% vs 2023 (€ 2,889,292) Favourable step	€ 2,244,656 Bank debt 2025: € 2,244,656 ▼ 13% vs 2024 (€ 2,580,448) Favourable step	▼ 13%
Balance sheet total	€ 4,769,704 Balance sheet total 2022: € 4,769,704 First fiscal year in the series	€ 4,804,376 Balance sheet total 2023: € 4,804,376 ▲ 1% vs 2022 (€ 4,769,704) Unchanged	€ 4,818,922 Balance sheet total 2024: € 4,818,922 Unchanged (€ 4,804,376) Unchanged	€ 4,788,393 Balance sheet total 2025: € 4,788,393 ▼ 1% vs 2024 (€ 4,818,922) Unchanged	▼ 1%

Key figures of R2 FARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 October 2026.

What happened to R2 FARMA?

What happened at R2 FARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Nov 27, 2025 New annual accounts for financial year 2025: profit of € 288,361 (▼ 18% vs 2024). filed late Source: NBB ↗
Dec 24, 2011 New establishment in Zaventem. KBO
Dec 24, 2011 Start of the company according to the CBE. KBO

In short

From € 273,966 profit in 2022 to € 288,361 profit in 2025.

Paid € 387,634 in corporate taxes since 2022.

Best year ever: 2024, with € 350,921 profit.

Original PDFs at the National Bank ↗

A new publication or filing at R2 FARMA? We notify you, reason included.

Follow R2 FARMA

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Leen Roggen 50%

Tim Roosens 50%

R2 FARMA

Apotheek Roosens 100%

Apotheek Roggen Zaventem 99%

Behind R2 FARMA are Leen Roggen and Tim Roosens. The shares are held by Leen Roggen (50%) and Tim Roosens (50%). It owns 100% of Apotheek Roosens and 99% of Apotheek Roggen Zaventem itself.

See the full network in the app

Directors

According to the 2025 annual accounts

Leen Roggen

Director

Owns 50% directly

Also active at: APOTHEEK ROGGEN ZAVENTEM

Tim Roosens

Director

Owns 50% directly

Also active at: APOTHEEK ROGGEN ZAVENTEM, APOTHEEK ROOSENS

Shareholders

Leen Roggen · director

50%

Tim Roosens · director

50%

Participations

Apotheek Roosens

100%

Apotheek Roggen Zaventem

99%

Establishments

Establishment units

Physical locations of this company

Registered office

Vilvoordelaan 74

1930 Zaventem

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0842.118.663
VAT number: BE 0842.118.663
Registered office: Vilvoordelaan 74, 1930 Zaventem
Names & denominations: R2 FARMA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 24 December 2011
Peppol: Active · Active since 1 Jan 2001
Activities · NACE: Overige zakelijke dienstverlening, neg

View on CBE Public ↗ Annual accounts (NBB) ↗